Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now early-phase tilt small index

Dermatitis: early-phase trial registry

2 of 7 indexed Dermatitis trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,497 of 28,707 conditions by registered trial count.

7 US clinical trials · 2 currently recruiting · #2,497 of 28,707 conditions by registered trial count

Dermatitis: 7 US clinical trials tracked, 2 recruiting.

Dermatitis is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Kimberly-Clark Corporation, running 1 of these trials.

Enrollment posture brief

Registry condition dermatitis

OPEN 2 | RECR 29% | LATE 0 | EARLY 4 | RANK #2497 | SPON 1

Nearest open-share peer: Acromegaly (29% recruiting · 14 trials)

ACL Tear71.4%ACL57.1%Acute Myelogenous Leukemia42.9%Dermatitis (this)29%Acne Scars28.6%
Open-enrollment share among volume-matched conditions near Dermatitis

Dermatitis lists 2 open slots (29% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Dermatitis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Dermatitis is recruiting below its size-band peers.

    2 of 7 indexed trials (28.6%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Dermatitis trials is spread across many organizations.

    Kimberly-Clark Corporation accounts for 1 of 7 trials (14.3%). 7 distinct sponsors appear on at least one study for this condition label.

  3. Typical Dermatitis enrolment sits around 96 participants.

    Median target enrolment is 96 among the 7 trials that report a genuine target (sentinel values excluded). 4 of those (57.1%) plan for fewer than 100 participants.

  4. Dermatitis research is mostly interventional.

    5 interventional and 2 observational studies make up this index (71.4% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 23

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 3

Named interventions

Most-linked intervention names on Dermatitis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

REGN668 Biological
1 trials
Patch Testing Procedure
1 trials
Phosphate Buffered Saline Other
1 trials
Artificial Fecal Insult Other
1 trials
Risankizumab Biological
1 trials
ATI-045 Drug
1 trials
Sodium hypochlorite Other
1 trials
Trimethoprim/sulfamethoxazole (TMP/SMZ) Drug
1 trials

US sites by state

Facility locations filed on Dermatitis trials. A trial with sites in several states counts in each.

Maryland 3 trials
Florida 3 trials
California 3 trials
Texas 2 trials
Michigan 2 trials
Illinois 2 trials
Arizona 2 trials
Pennsylvania 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Dermatitis page

7 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Dermatitis condition card totals 7 registered trials; most-linked intervention REGN668; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.